Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 309-311

  Thompson III, George R ^a,d   Wiederhold, Nathan P ^a,c,d   Fothergill, Annette W ^b   Vallor, Ana C ^a,d   Wickes, Brian L ^a   Patterson, Thomas F ^a,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; DRUG POTENTIATION; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; PYRIMIDINES; SEROTYPING; TRIAZOLES;

EID: 59749083143     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01216-08     Document Type: Article

References (21)

1. Brummer, E., K. Kamei, and M. Miyaji. 1998. Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study. Med. Mycol. 36:227-233.
2. Chen, S., T. Sorrell, G. Nimmo, B. Speed, B. Currie, D. Ellis, D. Marriott, T. Pfeiffer, D. Parr, and K. Byth, and Australasian Cryptococcal Study Group. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin. Infect. Dis. 31:499-508.
3. Chen, Y. C., S. C. Chang, C. C. Shih, C. C. Hung, K. T. Luhbd, Y. S. Pan, and W. C. Hsieh. 2000. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn. Microbiol. Infect. Dis. 36:175-183.
4. Ito-Kuwa, S., K. Nakamura, S. Aoki, and V. Vidotto. 2007. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses 50:277-281.
5. Khan, Z. U., H. S. Randhawa, T. Kowshik, A. Chowdhary, and R. Chandy. 2007. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J. Antimicrob. Chemother. 60:312-316.
6. Kidd, S. E., F. Hagen, R. L. Tscharke, M. Huynh, K. H. Bartlett, M. Fyfe, L. Macdougall, T. Boekhout, K. J. Kwon-Chung, and W. Meyer. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. USA 101:17258-17263.
7. Kwon-Chung, K. J., and J. E. Bennett. 1984. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120:123-130.
8. Kwon-Chung, K. J., I. Polacheck, and J. E. Bennett. 1982. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J. Clin. Microbiol. 15:535-537.
9. Kwon-Chung, K. J., T. Boekhout, J. W. Fell, and M. Diaz. 2002. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51:804-806.
10. Moraes, E. M., N. S. Primola, and J. S. Hamdan. 2003. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses 46:164-168.
11. Morgan, J., K. M. McCarthy, S. Gould, K. Fan, B. Arthington-Skaggs, N. Iqbal, K. Stamey, R. A. Hajjeh, and M. E. Brandt. 2006. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43:1077-1080.
12. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, G. V. Doern, and D. J. Diekema. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163-2167.
14. Saag, M. S., R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, J. D. Sobel, and W. E. Dismukes, and Infectious Diseases Society of America. 2000. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30:710-718.
15. Schwarz, P., G. Janbon, F. Dromer, O. Lortholary, and E. Dannaoui. 2007. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 51:383-385.
16. Seifert, H., U. Aurbach, D. Stefanik, and O. Cornely. 2007. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51:1818-1821.
17. Sorrell, T. C. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-168.
18. Speed, B., and D. Dunt. 1995. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis. 21:28-34.
19. Tay, S. T., T. Tanty Haryanty, K. P. Ng, M. Y. Rohani, and H. Hamimah. 2006. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 49:324-330.
20. Reference deleted.
21. Trilles, L., B. Fernandez-Torres, S. Lazera Mdos, B. Wanke, and J. Guarro. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42:4815-4817.